Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Rhea-AI Summary
Scribe Therapeutics (Nasdaq: SCTX) closed its upsized initial public offering of 9,867,000 common shares, including 1,287,000 additional shares from the underwriters’ fully exercised option, at $15.00 per share. All shares were issued by the company, whose stock began trading on the Nasdaq Global Market on July 24, 2026 under ticker SCTX.
According to Scribe Therapeutics, aggregate gross proceeds from the IPO and a concurrent private placement totaled approximately $155.51 million before underwriting discounts and commissions. The private placement comprised 500,000 shares sold to Sanofi at the IPO price. Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers.
Positive
- Gross proceeds of ~$155.51 million from IPO and private placement before fees
- 9,867,000 IPO shares sold at $15.00 each, all issued by the company
- Underwriters’ option for 1,287,000 additional shares was fully exercised
- Concurrent private placement of 500,000 shares to Sanofi at IPO price
- Shares now listed on Nasdaq Global Market under ticker SCTX
Negative
- All 10,367,000 newly issued shares (IPO plus private placement) dilute existing equity holders
News Explained
The completed issuance reduces existing holders’ percentage ownership, while Sanofi’s 500,000 private-placement shares carry a later-resale registration constraint.
Scribe Therapeutics has completed the IPO and concurrent private placement, and issuing those shares increases total share count and reduces existing holders’ percentage ownership absent offsetting changes.
The
Market reaction after initial public offering closing: SCTX -4.80% in the Jul 28 session
In the Jul 28 session, SCTX declined 4.80%, reflecting a moderate negative market reaction. Argus tracked a trough of -16.4% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Key Terms
initial public offering financial
private placement financial
underwriters’ option financial
registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today announced the closing of its upsized initial public offering of 9,867,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,287,000 additional shares, at the initial public offering price of
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers for the offering.
The aggregate gross proceeds to Scribe Therapeutics from the initial public offering, including full exercise of the underwriters’ option to purchase additional shares and the concurrent private placement, before deducting underwriting discounts and commissions, were approximately
A registration statement relating to the securities issued and sold in the initial public offering has been filed with the U.S. Securities and Exchange Commission (the “SEC”) and became effective on July 23, 2026. A prospectus relating to and describing the terms of the initial public offering has been filed with the SEC and is available on the SEC's website at www.sec.gov. The initial public offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at syndicate@leerink.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and Wells Fargo Securities, LLC, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at (800) 645-3751 (option #5) or by email at WFScustomerservice@wellsfargo.com.
In addition to the shares sold in the initial public offering, Scribe Therapeutics today announced the closing on July 27, 2026 of its sale of 500,000 shares of its common stock at the initial public offering price per share in a concurrent private placement to Sanofi. The sale of the shares of common stock in the concurrent private placement was not registered under the Securities Act of 1933, as amended.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Scribe, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design™ approach and nature’s blueprint for improved cardiovascular health, Scribe’s initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company’s lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
